174274-85-2

Usage

Uses

Used in Pharmaceutical Industry:
2-tert-butyl-5-nitro-1H-indole is used as a building block for the production of various drugs and pharmaceutical intermediates. Its unique structure and functional groups contribute to the development of new therapeutic agents.
Used in Organic Synthesis:
2-tert-butyl-5-nitro-1H-indole is used as a key intermediate in the synthesis of complex organic molecules, facilitating the creation of diverse chemical entities with potential applications in various fields.
Used in Antimicrobial Applications:
2-tert-butyl-5-nitro-1H-indole is studied for its potential antimicrobial properties, offering a possible alternative for combating resistant bacteria and other microorganisms.
Used in Cytotoxicity Research:
2-tert-butyl-5-nitro-1H-indole is also investigated for its cytotoxic effects, which may have implications in cancer research and the development of novel anticancer agents.
Handling and Storage:
Due to its high melting point and potential reactivity and toxicity, 2-tert-butyl-5-nitro-1H-indole requires careful handling and storage to ensure safety and stability.

Upstream product

• 1805-65-8 2-tert-butylindole 
• 917-92-0 3,3-Dimethylbut-1-yne 
• 615-43-0 2-iodophenylamine 
• 116491-51-1 2-(3,3-dimethyl-1-butynyl)aniline 
• 682357-48-8 2-(3',3'-dimethylbut-1-ynyl)-4-nitroaniline 

Downstream Products

• 682357-49-9 2-tert-butyl-1H-indol-5-ylamine 

Relevant academic research and scientific papers

SUBSTITUTED INDOLES AND THEIR USE AS HCV INHIBITORS

The present invention comprises indole-derivatives that are inhibitors of HCV. Composition comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and compositions to inh

High-affinity inhibitors of dihydrofolate reductase: Antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size

A series of 7,8-dialkylpyrrolo[3,2-f]quinazolines were prepared as inhibitors of dihydrofolate reductase (DHFR). On the basis of an apparent inverse relationship between compound size and antifungal activity, the compounds were designed to be relatively small and compact. Inhibitor design was aided by a GRID analysis of the three-dimensional structure of Candida albicans DHFR, which suggested that relatively small, branched alkyl groups at the 7- and 8-positions of the pyrroloquinazoline ring system would provide optimal interactions with a hydrophobic region of the protein. The compounds were potent inhibitors of fungal and human DHFR, with K(i) values as low as 7.1 and 0.1 pM, respectively, and were highly active against C. albicans and an array of tumor cell lines. In contrast to known lipophilic inhibitors of DHFR such as trimetrexate and piritrexim, members of this series of pyrroloquinazolines were not susceptible to P-glycoprotein-mediated multidrug resistance and also showed significant distribution into lung and brain tissue. The compounds were active in lung and brain tumor models and displayed in vivo activity against Pneumocystis carinii and C. albicans.